Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Samsung Biologics Signs $262 Million Manufacturing Agreement With European Pharma Company Through 2033

Sep 11, 2026•about 3 hours ago

Contract Type

agreement

South KoreaManufacturingBiotechnology

Description

Samsung Biologics has entered into a $262 million manufacturing agreement with a European pharma company, reinforcing its manufacturing capabilities until 2033. This deal highlights the strong demand for their services and boosts the company's cumulative contract value to over $21.9 billion.

Company Information

Company

Samsung Biologics

Location

South Korea

About

Samsung Biologics is a fully integrated contract development and manufacturing organization (CDMO) that offers comprehensive services from cell line development to final aseptic fill/finish. The company operates state-of-the-art, CGMP compliant facilities and has increased its biomanufacturing capacity to meet growing demand. With a commitment to innovative technologies and customized solutions, Samsung Biologics supports its clients' evolving needs in the biopharmaceutical sector. The company also has a presence in the U.S. and Europe to better collaborate with international clients.

Related People

Suggested for you
Yong
Likely contact at this company
••••••••@••••••••

See Yong's verified email →

Kevin
Likely contact at this company
••••••••@••••••••

See Kevin's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Samsung Biologics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Samsung Biologics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.